Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/11147/7148
Browse
2 results
Search Results
Article Review of the Relationship Between Growth Hormone and SARS-CoV-2 Infection(Taylor & Francis Ltd, 2025) Rasmi, Yousef; Kirboga, Kevser Kubra; Roshanravan, Neda; Tekin, Burcu; Jalali, Ladan; Ghazizadeh, FaridRecent evidence suggests that SARS-CoV-2 is associated with the endocrine system, particularly growth hormone (GH). GH modifies immune responses and its deficiency could be responsible for the uncontrolled immunity that occurs in severe cases of COVID-19. Recent research shows that patients suffering from lung complications have significantly lower levels of GH and insulin-like growth factor-1 (IGF-1), which are proportionate to the severity of the disease. This relationship supports the hypothesis that GH regulates the immunity and inflammatory processes of the SARS-CoV-2 virus. However, variables such as age, gender, and comorbidities, such as diabetes and obesity, which are associated with lower GH levels, are strong predictors of COVID-19 outcomes. Older individuals and men, who tend to have lower GH levels, are disproportionately represented among severely ill patients. The available evidence suggests that GH supplementation therapy should be evaluated as a supportive measure to reduce the severity of the disease in high-risk individuals. The main goal of the research is to understand how COVID-19 is related to GH so that researchers can identify new mechanisms of pathology and develop better solutions for patients.Review Citation - WoS: 23Citation - Scopus: 24Microfluidic-Based Technologies for Diagnosis, Prevention, and Treatment of Covid-19: Recent Advances and Future Directions(Springer, 2023) Tarım, Ergün Alperay; Anıl İnevi, Müge; Özkan, İlayda; Keçili, Seren; Bilgi, Eyüp; Başlar, Muhammet Semih; Özçivici, Engin; Öksel Karakuş, Ceyda; Tekin, Hüseyin CumhurThe COVID-19 pandemic has posed significant challenges to existing healthcare systems around the world. The urgent need for the development of diagnostic and therapeutic strategies for COVID-19 has boomed the demand for new technologies that can improve current healthcare approaches, moving towards more advanced, digitalized, personalized, and patient-oriented systems. Microfluidic-based technologies involve the miniaturization of large-scale devices and laboratory-based procedures, enabling complex chemical and biological operations that are conventionally performed at the macro-scale to be carried out on the microscale or less. The advantages microfluidic systems offer such as rapid, low-cost, accurate, and on-site solutions make these tools extremely useful and effective in the fight against COVID-19. In particular, microfluidic-assisted systems are of great interest in different COVID-19-related domains, varying from direct and indirect detection of COVID-19 infections to drug and vaccine discovery and their targeted delivery. Here, we review recent advances in the use of microfluidic platforms to diagnose, treat or prevent COVID-19. We start by summarizing recent microfluidic-based diagnostic solutions applicable to COVID-19. We then highlight the key roles microfluidics play in developing COVID-19 vaccines and testing how vaccine candidates perform, with a focus on RNA-delivery technologies and nano-carriers. Next, microfluidic-based efforts devoted to assessing the efficacy of potential COVID-19 drugs, either repurposed or new, and their targeted delivery to infected sites are summarized. We conclude by providing future perspectives and research directions that are critical to effectively prevent or respond to future pandemics.